Biotech … The Breakdown

Wedge Break Has Been Tested

It’s been a while since we’ve talked about the chief cook and bottle washer in this whole financial collapse scenario.

However, biotech has not been forgotten.

There are two indices (ETFs) being tracked: IBB and SPBIO.

Both entered bear market territory long ago. SPBIO topped out, way back in February 2021; IBB topped later, in August the same year.

Leveraged inverse funds are LABD, and BIS, respectively. LABD is 3X inverse with BIS a 2X inverse.

The Long Term

One thing unique to David Wies, was to look at the long term: Monthly, Quarterly and Yearly charts.

Doing so, puts one in a strategic mindset … not easily swayed by the latest prattle from media sources.

If we look at biotech, IBB, on a quarterly basis we have the following chart.

Biotech IBB, Quarterly

The mark-up of this chart is where it gets interesting.

A terminating wedge that’s been over seven years in the making has just broken to the downside.

Not only that, when we get closer-in (on the weekly), we can see the wedge break has been tested and now today, appears to be reversing to the downside (shown on daily).

Biotech IBB, Weekly

With zoom

The daily shows a Fibonacci retrace to 38%; then today, a downside reversal.

You can see where this is going.

Based on the above analysis a short position in IBB, has been opened via BIS (not advice, not a recommendation).

The trade is BIS-22-01, with an (initial) entry @ 28.5173

Summary

The news on specific biotech companies is already out if one knows where to look.

Stated time and again on this site, we’re just in the beginning stages of the repercussions.

It even looks like they’ve moved on from the initial scam and are cooking up a new one.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Last Time … is not … This Time

The Rule of Alternation

That’s it in a nutshell. What happened last time, won’t happen this time.

The market reveals its own secrets; you just have to know where to look.

An entire industry has been (purposely) built to make sure the ‘average investor’ never finds the truth of the markets.

That industry is the financial analysis industry; the one with the P/E ratios, Debt-to-Equity, and so on.

Sure, it was a tongue-in-cheek post to use the fact that Carvana had no P/E (linked here).

I’m not certain if they ever had a P/E; probably not.

However, that financial, i.e., fundamental(s) fact, did not keep the stock from going up over 4,529%, in four years.

It should be noted, the Carvana analysis was done on a Saturday (as has this one). At the very next trading session, CVNA posted lower, started its decline in earnest and never looked back.

Not saying that exact thing (timing it to the day) will happen with our next candidate real estate; as said before, part of Wyckoff analysis (a lot of it, actually) is straight-up intuition.

The good part from a computer manipulated and controlled market perspective, intuition can’t be quantified.

So, that’s your edge.

Let’s move on to ‘last time is not this time’ and see what the real estate market IYR, is telling us.

Weekly Chart, IYR

We’ve got the weekly un-marked chart of IYR, below.

The ‘alternation’ is there.

Here it is, close-up.

The first leg lower had some initial smoothness but quickly became choppy and overlapping.

Not so, now.

We’re essentially heading straight down.

Fundamentals

From a fundamental standpoint, real estate is finished. However, it’s been finished for a long time.

The fundamentals won’t and can’t tell anyone what’s likely to happen at the next trading session … or any other session.

The market itself (shown above) is saying the probabilities are for a continued decline; posting smooth long bars until some meaningful demand is encountered.

As shown on the last post, if the trading channel is in-effect, that (chart) demand is a long way down.

Positioning

Shorting IYR via DRV, has been covered in previous posts (search for DRV-22-02).

The following weekly chart, is marked up with two arrows.

Arrow No. 1

Initial short position via DRV was opened late in the day on April 28th; the day before the market broke significantly lower (not advice, not a recommendation).

Arrow No. 2

As the market headed lower during the week just ended, the size of the DRV position was increased by 36%.

Currently, the gain on the total position is about +22%.

At this juncture, the DRV stop is located well in the green in the unlikely event we get a sharp IYR, upward move in the coming week.

Summary

Under ‘normal’ conditions one could expect some kind of upward bounce in the days ahead.

However, as shown already with big cap leader PLD, the situation’s anything but normal.

Highlighted in earlier posts, biotech is leading the way with SPBIO, currently down – 59.8%, from its highs.

Biotech IBB, with chief cook and (globalist) bottle washer Moderna (MRNA), is down – 36.2%.

As Dan from i-Allegedly has stated time and again, we’re already in a depression.

So, buckle your seatbelt Dorothy …

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Bears To Seize Control ?

World Chaos, Continues

The long-time reasoning behind this site’s ‘short only‘ trading plan, is becoming abundantly clear.

For years, there have been no ‘long’ trades on anything except leveraged inverse funds.

The premise? A ‘disconnect’ can happen at any time.

At this point, we’re getting to see those potential disconnects in real-time on a near continuous basis.

The past week bled-off the massive put leveraging; thus, setting the market up for (potential) downside reversal.

Getting Back To ‘Normal’

Those who bought the dip in Pavlovian fashion, may be thinking at some point, we’ll get back to ‘normal’.

News Flash:

What’s happening now, Is The Normal.

This is how it’s going to be on a go-forward basis.

Conflict, shortages, supply chaos, weather weaponry, nuclear saber rattling, bank runs are now, all normal.

With that, let’s look at last week’s markets and the set-up for the week ahead.

The SOXX, Rebounds

The last update discussed being short the semiconductors via inverse fund SOXS (not advice, not a recommendation).

The stop was hit, and that position (SOXS-22-02) has been closed out with a gain of about 6.2%.

Note how in the daily chart below, price action came right up to the stop level shown previously, then penetrated that level ever so slightly.

The ‘market’ knows where you are.

Being (stopped) out lets one look for a better opportunity.

Biotech (SPBIO), The Next Set-Up:

Turns out that biotech, SPBIO, may be at a low-risk juncture for a short via leveraged inverse fund LABD (not advice, not a recommendation).

Yesterday’s post highlighted some of the reasons for a biotech reversal.

The analysis below, builds on that reversal potential.

The weekly chart of SPBIO, has a channel and Fibonacci time correlation(s).

The next chart zooms-in on a possible target for a move lower.

Leveraged Inverse, LABD

Another reason to think SPBIO, is ready to continue downward, can be seen on the 4-Hour chart of LABD.

The prior report had daily range narrowing.

Getting closer into the action, we see the 4-Hour range narrowing as well.

In addition, down-thrust energy (Force Index) for Friday’s move appears to be exhausted.

Positioning

Early or late? If you’re trading professionally, that decision must be made ahead of time.

Some traders like to wait for ‘confirmation’ of a move and there’s nothing wrong with that.

For this author however, waiting for confirmation means I’m late. I’m behind the curve and ‘chasing’ the market.

With that said, LABD was entered towards the end of the session on Friday at 41.05 (not advice, not a recommendation).

We’ll find out soon enough, if Monday’s open will be in-the-green.

Summary:

Even as this post is being created, world news continues to pour in … this time, from North Korea.

Anything can happen in the coming week. The markets could somehow ‘shake-off’ all of the news and move higher.

However, probability suggests market continuation to the downside.

At this juncture, we’re about six hours before the Sunday futures open.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech … Ready To Reverse

Highly leveraged (3X Inverse of SPBIO), LABD, looks ready for upside reversal.

The next chart shows trendline contacts.

Volume increased on Friday while the trading range narrowed significantly.

The next chart’s a little busy but zooms in on the volume and the daily range in question.

The overall markets have rebounded during the past two trading days.

Inverse funds have declined correspondingly.

Interestingly, LABD seems to have maintained its upward bias (down for SPBIO) better than other inverse funds like SDS, DXD, SOXS, QID and TZA.

Summary:

For downside action, one wants to look for the weakest sector.

Look for a new daily LABD high on Monday, (new low for SPBIO).

This is a typical entry signal with stops at the last session’s low; currently LABD, 40.08 (not advice not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

‘Heart Failure’ … The New Normal

… What It Could Mean For Biotech

So, now it starts.

This just out from ZeroHedge, linked here, shows the ‘elephant’ has begun to go mainstream.

Another chess-move.

At least one previous post (No.1, linked here), has shown the phenomenon is not a one-off event.

Now, according to the link above, there’s an estimated 300,000 affected … and we’re just getting started.

Insiders Sell … Retail Buys

Do those at the highest levels know their customer base is about to evaporate on a world-wide basis?

While they may not know every detail, they at least know something’s up. Steven Van Metre discusses the insider selling in his latest update, linked here.

Front End Phenomenon

We’re still at the beginning stages of an event that in the opinion of this author, is going to last the lifetime of those reading this post.

‘Hyperbolic statement’ one might say.

To that, I would counter with this; when it was posted, the ‘elephant’ was hyperbolic as well.

Now? Not so much.

Keeping that long range thinking in mind also keeps one from choosing the ‘insane’ human behaviors discussed by Dan (I Allegedly) in his latest post.

So, let’s take a look at what type of insanity we have going on in the markets today.

Of course, that points us to our chief cook and bottle washer, biotech (IBB).

Biotech, IBB

When we last left our hero, savior, and protector of all that is natural immunity, the biotech discussion was on Moderna (MRNA).

The thrust higher, detailed in this post was thought to be too fast for a sustained reversal. Well, it was right and wrong at the same time.

Moderna wound up reversing … sort of.

At the same time, the biotech sector headed lower to support and is now moving higher.

The weekly IBB, chart has the support (lower blue line) and potential up-thrust location (also 50%, retrace) identified.

The zoom shows the narrow gap between the weekly bars and 50% retrace.

If price action makes it past the resistance bars and into the gap, IBB would then be in up-thrust position (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279


Panic In The Streets …

Remain Calm. All, Is Well.

All, Is Well !!!

It certainly feels like Animal House, doesn’t it?

A bunch of idiots running around, glued to the mainstream narrative.

However, let’s not digress but rather get to the chief cook and bottle washer at hand.

Moderna (MRNA) and Biotech (IBB).

Biotech: MRNA, IBB

Moderna’s move above resistance (‘Target’ level in this update) seems too fast for up-thrust and reversal.

It could reverse from here.

However, the more likely scenario is the mainstream milks this whole thing all the way to Christmas and beyond.

That brings us to the sector itself, IBB:

We’ll go straight to the marked-up (daily) chart.

It’s starting to look familiar isn’t it?

Spring-to-Up-Thrust … Spring-to-Up-Thrust

But wait … there’s more!

A Fibonacci 21-Days from the most recent IBB, low on November 23rd, puts the date at December 22; The Winter Solstice.

How convenient.

Of course, anything can happen between now and then. At least we have a potential target and scenario.

As with the gold miner’s (GDX) short that’s still on-going (not advice, not a recommendation), we get to see how it all plays out.

Will Biotech, IBB, be in up-thrust (reversal) position, on or around December 22nd?

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

… Cue The ‘Hype’

Right On Schedule … A New ‘Variant’

Seems like just yesterday, we were saying:

“There’s all kinds of nastiness in the guise of ‘new strains’ out there; likely to raise their heads before Christmas and probably after as well.”

Wait, … that really was, yesterday.

So, now we have the ‘Nu variant’.

Get it? A, new variant. 🙂

The ‘Epsilon’ variant (from the idiot in Brave New World) is probably being saved for last … because if anyone’s still believing the hype by that time, it won’t matter … they’ll be fully ‘boosted’.

That doesn’t mean the pros can’t make money off the herd … while there still is a herd.

Which brings us to today’s underside test action of MRNA.

Moderna (MRNA):

Well, that retrace was quick.

First, let’s show yesterday’s weekly chart.

And now, today’s

It’s true that price action is testing the underside.

However, if we go to the daily chart (below), we can see if price action can make it just a bit higher … to the 360 – 380 area, then we have an up-thrust (potential reversal) condition.

The chart looks similar to our gold (GLD) up-thrust target, linked here for reference.

Recall, for that set-up, it took two months for GLD, to penetrate resistance … and then go into a vicious reversal.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech, At The Danger Point

In More Ways Than One

For now, we’ll discuss only the technical aspects.

We’ll leave the rest of the truth for mainstream news.

Discussed previously, the sector (SPBIO) was left with our assessment that it may reverse higher into a retrace; combined with an up-thrust/reversal.

That was then.

Biotech, SPBIO, Now:

Daily un-marked chart of SPBIO:

Below, a marked-up chart showing penetration and move off support (Spring Condition).

Included, is the 38% retrace level … location for potential test and reversal:

As with the on-going reversal in gold (GLD) and the miners, GDX, GDXJ, we’ll have to see how this plays out.

Unfortunately, as we head into what used to be the regular flu season, those who received ‘protection’, are going to find out they’re not protected at all.

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Peak Oil ?

Will Demand Collapse Faster Than Supply Contracts ?

Is There A Biotech Connection ?

The Next Chess Move

Everyone’s good at telling you what the problem is; it’s a financial collapse !!!

No, Duh!

The hard part is, how to position for the unknown at least for those of us in the serfdom.

The so-called elites, the oligarchs know (or think they know) exactly what’s happening.

They move their chess players and we move ours. The goal is to position for (potential) profit with the caveat we all make it out on the other side.

Personal Anecdote (skip to XOP Analysis if not interested):

I have a close family member that’s been a school teacher for about twenty years. He/She is well known in the local town and has a significant number of connections.

Because the children being taught are typically small, ranging from kindergarten to fourth grade, those kids tend to reveal all that’s happening at home.

Their revelations include financial status (or lack of), political leanings as well as abuse that’s happening physically and sexually. It’s the real deal.

As an aside, any potential crimes are fully documented and reported.

The point here is, this contact has revealed that children, family members and extended family members are severely ill or dropping dead after receiving an ‘injection’.

However, the surviving family members are just too stupid (or afraid) to put it together; the injections are causing the deaths.

It’s some kind of mental block and/or mass hypnosis.

It’s wrenching and heartbreaking.

However, at the same time and this is where it gets harsh, for those of us in the faith, we know Biblical scripture tells us the Lord delights in hiding the truth.

One has to diligently seek out truth. It takes work and a prayerful form of neural plasticity; the ability to be mentally flexible.

Truth is not for the lazy, the incompetent, the coward.

Why should immutable truth come to a coward or idiot that does not diligently seek it?

New ‘Variant’:

The rapidly increasing deaths may be passed off by the mainstream media as some kind of new ‘variant’.

That ‘variant’ brings us to the market at hand; oil and oil exploration XOP and possible biotech connection.

XOP Analysis:

As with biotech SPBIO, and its leveraged inverse fund LABD, so too we have Oil & Gas Exploration XOP, and leveraged inverse fund DUG.

The long term un-marked, weekly chart of XOP:

Next, we have price action contacting a multi-year trendline:

Moving closer on the weekly, we have a terminating wedge:

Terminating wedge(s) typically result in price action moving opposite of wedge formation.

In the case above, that would be a reversal to the downside.

This past week’s bar was a reversal. It’s a potential signal the formation is complete and XOP is ready for the downside.

Of course, if XOP is about to head lower, inverse DUG is about to head higher (not advice, not a recommendation).

Daily chart of DUG.

The Biotech (SPBIO) Connection:

The weekly chart of SPBIO, shows momentum on downward thrusts has slowed. The black dashed arrow’s trajectory is becoming more shallow:

If biotech is going to retrace, the solid blue line is a Fibonacci 38%, as well as potential location for an up-thrust (downside reversal).

A new variant (which is likely injection injury) may be used by the media to drive biotech higher to the retrace level.

We’ll have to wait and see if there’s a reduction of the population as we head into the end of the year. It’s a known fact, the injection destroys the immune system … so far, permanently.

That would be a factor in the up-coming flu season.

Remember that?

We used to have a regular flu season … but that all disappeared (re-branded, actually) with our current situation.

Summary:

Nearly all recessions have started with rising oil prices.

However, we’re not in a recession but an all out collapse. The economy is contracting at the fastest rate in U.S. history.

Our current position is demand will collapse faster than supply restriction (not advice, not a recommendation).

Or, we could still have rising oil prices but it won’t be enough to offset the cost of drilling and production; lack of demand may be overwhelming.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech: Last Squeeze ?

Whack The Bears One-More-Time

The daily chart above, shows our current location.

Inverting the chart and expanding the price action gives us the following:

Was today an attempt to break the up-trend (down-trend, non-inverted)?

Wyckoff called this type of sharp adverse move ‘threatening action’.

You won’t know if the market’s going to carry out the threat until the next session or subsequent sessions.

Positioning:

My firm’s (core) short position remains unchanged (not advice, not a recommendation).

However, the main account holding of LABD, was reduced by approximately 2.9%, during this session to adjust for margin requirements.

It’s important to note, the after hours session is already trading about 1% higher (for inverse LABD); a typical occurrence when the day’s move was a shakeout.

We’ll see if that action carries over to the regular session tomorrow.

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279